Drug Allergy, Neuromuscular Blockade
Conditions
Brief summary
The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.
Interventions
None listed
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.
Exclusion criteria
* Patients who have received immunomodulators, immunosuppressants, etc. * Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.) * Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * Other cases where the Principal Investigator determines that it is difficult to conduct the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptomic profile analysis of the T lymphocytes by RNA sequencing | until end of surgery (usually up to 12 hours from the first dose of rocuronium) | Blood sample from the patients when patient shows allergic reaction after administration of rocuronium |
Countries
South Korea
Outcome results
None listed